These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 29445031)
21. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983 [TBL] [Abstract][Full Text] [Related]
22. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081 [TBL] [Abstract][Full Text] [Related]
23. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient. Njoroge SW; Burgess KR; Cobleigh MA; Alnajar HH; Gattuso P; Usha L Breast Cancer Res Treat; 2017 Nov; 166(1):315-319. PubMed ID: 28702897 [TBL] [Abstract][Full Text] [Related]
24. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Recommendation Statement. Am Fam Physician; 2020 Feb; 101(4):233-238. PubMed ID: 32053325 [No Abstract] [Full Text] [Related]
25. Hereditary breast and ovarian cancer syndrome: considering the complexities. Senter L Curr Probl Cancer; 2014; 38(6):226-34. PubMed ID: 25497409 [TBL] [Abstract][Full Text] [Related]
26. The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. Afghahi A; Kurian AW Curr Treat Options Oncol; 2017 May; 18(5):27. PubMed ID: 28439798 [TBL] [Abstract][Full Text] [Related]
27. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859 [TBL] [Abstract][Full Text] [Related]
28. HBOC multi-gene panel testing: comparison of two sequencing centers. Schroeder C; Faust U; Sturm M; Hackmann K; Grundmann K; Harmuth F; Bosse K; Kehrer M; Benkert T; Klink B; Mackenroth L; Betcheva-Krajcir E; Wimberger P; Kast K; Heilig M; Nguyen HP; Riess O; Schröck E; Bauer P; Rump A Breast Cancer Res Treat; 2015 Jul; 152(1):129-136. PubMed ID: 26022348 [TBL] [Abstract][Full Text] [Related]
29. Cancer Genetic Counseling and Testing in an Era of Rapid Change. Hooker GW; Clemens KR; Quillin J; Vogel Postula KJ; Summerour P; Nagy R; Buchanan AH J Genet Couns; 2017 Dec; 26(6):1244-1253. PubMed ID: 28434142 [TBL] [Abstract][Full Text] [Related]
31. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Daly MB; Pilarski R; Berry M; Buys SS; Farmer M; Friedman S; Garber JE; Kauff ND; Khan S; Klein C; Kohlmann W; Kurian A; Litton JK; Madlensky L; Merajver SD; Offit K; Pal T; Reiser G; Shannon KM; Swisher E; Vinayak S; Voian NC; Weitzel JN; Wick MJ; Wiesner GL; Dwyer M; Darlow S J Natl Compr Canc Netw; 2017 Jan; 15(1):9-20. PubMed ID: 28040716 [TBL] [Abstract][Full Text] [Related]
32. Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication. Pelttari LM; Shimelis H; Toiminen H; Kvist A; Törngren T; Borg Å; Blomqvist C; Bützow R; Couch F; Aittomäki K; Nevanlinna H Clin Genet; 2018 Mar; 93(3):595-602. PubMed ID: 28802053 [TBL] [Abstract][Full Text] [Related]
33. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Giri VN; Knudsen KE; Kelly WK; Abida W; Andriole GL; Bangma CH; Bekelman JE; Benson MC; Blanco A; Burnett A; Catalona WJ; Cooney KA; Cooperberg M; Crawford DE; Den RB; Dicker AP; Eggener S; Fleshner N; Freedman ML; Hamdy FC; Hoffman-Censits J; Hurwitz MD; Hyatt C; Isaacs WB; Kane CJ; Kantoff P; Karnes RJ; Karsh LI; Klein EA; Lin DW; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann MJ; Mark JR; McCue PA; Miner MM; Morgan T; Moul JW; Myers RE; Nielsen SM; Obeid E; Pavlovich CP; Peiper SC; Penson DF; Petrylak D; Pettaway CA; Pilarski R; Pinto PA; Poage W; Raj GV; Rebbeck TR; Robson ME; Rosenberg MT; Sandler H; Sartor O; Schaeffer E; Schwartz GF; Shahin MS; Shore ND; Shuch B; Soule HR; Tomlins SA; Trabulsi EJ; Uzzo R; Vander Griend DJ; Walsh PC; Weil CJ; Wender R; Gomella LG J Clin Oncol; 2018 Feb; 36(4):414-424. PubMed ID: 29236593 [TBL] [Abstract][Full Text] [Related]
34. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627 [TBL] [Abstract][Full Text] [Related]
35. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition. Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234 [TBL] [Abstract][Full Text] [Related]
36. Hereditary cancer syndromes, their testing and prevention. Foretová L Cas Lek Cesk; 2019; 158(1):15-21. PubMed ID: 31046387 [TBL] [Abstract][Full Text] [Related]
37. Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk. O'Leary E; Iacoboni D; Holle J; Michalski ST; Esplin ED; Yang S; Ouyang K Ann Surg Oncol; 2017 Oct; 24(10):3060-3066. PubMed ID: 28766213 [TBL] [Abstract][Full Text] [Related]
38. Dominant negative ATM mutations in breast cancer families. Chenevix-Trench G; Spurdle AB; Gatei M; Kelly H; Marsh A; Chen X; Donn K; Cummings M; Nyholt D; Jenkins MA; Scott C; Pupo GM; Dörk T; Bendix R; Kirk J; Tucker K; McCredie MR; Hopper JL; Sambrook J; Mann GJ; Khanna KK J Natl Cancer Inst; 2002 Feb; 94(3):205-15. PubMed ID: 11830610 [TBL] [Abstract][Full Text] [Related]
39. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J; Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971 [TBL] [Abstract][Full Text] [Related]
40. Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients. DeLeonardis K; Sedgwick K; Voznesensky O; Matloff E; Hofstatter E; Balk S; Tung N Breast J; 2017 Jul; 23(4):461-464. PubMed ID: 28139868 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]